Clinical Trial Search

Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV

Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants

Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability

Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants

Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities

Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants

Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants

Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Progression-free Survival (PFS) — 91.3 percentage of participants

Primary: Percentage of Patients With ≥50% Seizure Reduction During the Maintenance Period Compared With Seizure Frequency Before Initiation of Perampanel

Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants

Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants

Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants

Primary: Central Nervous System (CNS) Toxicity — 1 participants

Primary: Number of Phase I Participants Experiencing Toxicity — 1; 3 Participants

Primary: Number of Participants With Objective Response — 4; 5; 12; 10 Participants

Primary: Number of Patients Assessed for Toxicity According to CTC Version 3.0 — 25 participants

Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…

Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants

Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants

Primary: Overall Survival (OS) — 10.2; 11.64 months

Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants

Primary: 1-year Overall Survival (OS) — 80 percentage of participants